Table 2.

Clinical outcome according to IGFBP2 mRNA expression

Clinical Outcome	IGFBP2 low	IGFBP2 high	P
Resistant disease†
Resistant/total [no. (%)]	20/63 (32)	13/20 (65)	0.02
Complete remission rate‡
CR/total [no. (%)]	43/73 (59)	7/25 (28)	0.01
Death in induction therapy‡
Death/total [no. (%)]	10/73 (14)	5/25 (20)	0.52
Relapse rate$
Relapse/total [no. (%)]	12/25 (48)	2/6 (33)	0.66
Median remission duration¶
[years (95% CI)]	2.8 (1.9–3.8)	3.0 (1.4–4.7)	0.67
Overall survival¶¶			0.53
Alive at 2 years [% (95% CI)]	57 (39–75)	48 (18–78)
Median survival [years (95% CI)]	3.3 (2.5–4.2)	2.8 (1.6–4.1)

CR: complete remission, CI: confidence interval.

^†N=83. One patient who did not complete induction therapy and 15 patients who died during induction therapy were excluded.

^‡N=98. One patient who did not complete induction therapy was excluded.

^$N=31. Patients who received SCT in first CR were excluded.

^¶N=49. Patients who received SCT in first CR were censored at the time of transplantation.

^¶¶N=98. One patient with development of second neoplasia was excluded. Patients who received SCT in first CR were censored at the time of transplantation.